Medicine:AdCLD-CoV19
From HandWiki
Short description: Vaccine candidate against COVID-19
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | viral |
| Clinical data | |
| Routes of administration | Intramuscular |
AdCLD-CoV19 is a COVID-19 vaccine candidate developed by Cellid Co,[1][2] a company from South Korea.[3]
A phase 1/2 trial of a single injection of AdCLD-CoV19 began in December 2020 in South Korea.[4] In September 2021, a phase 1 trial began for a single injection of another version, named AdCLD-CoV19-1.[5] Preclinical studies of a single dose in mice and non-human primates for this vaccine candidate were published in April 2022.[6] In August 2022, a phase 2 trial of 1 or 2 doses of AdCLD-CoV19-1 was registered.[7]
References
- ↑ "LG Chem pushes for Covid-19 vaccine CMO deal". Korea Biomedical Review. 10 December 2020. http://www.koreabiomed.com/news/articleView.html?idxno=9876.
- ↑ "Covid-19 vaccine trials stalled by rare chance to get licensed vaccines". Korea Biomedical Review. 11 August 2021. https://www.koreabiomed.com/news/articleView.html?idxno=11877.
- ↑ "Cellid Co Ltd, Company Profile and News". Bloomberg Markets. https://www.bloomberg.com/profile/company/299660:KS.
- ↑ Clinical trial number NCT04666012 for "Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers" at ClinicalTrials.gov
- ↑ Cellid Co (21 January 2022). "A Dose Escalation, Multicenter, Open, Phase I Study to Assess the Safety and Immunogenicity of AdCLD-CoV19-1, a COVID-19 Preventive Vaccine in Healthy Volunteers.". National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT05047692.
- ↑ "The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates". Vaccines 10 (5): 712. April 2022. doi:10.3390/vaccines10050712. PMID 35632468.
- ↑ Cellid Co (27 August 2022). A Phase IIb, Multicenter, Observer-Blinded, Randomized, Placebo-Controlled Trial to Evaluate the Immunogenicity and Safety of the AdCLD-CoV19-1 in Healthy Adults Aged 19 Years Old and Above. National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT05520970. Retrieved 27 September 2022.
 |
